Probing the Mechanisms of Intradialytic Hypertension
Authors:
- Jula K. InrigJIJula K. Inrig
- Peter Van BurenPBPeter Van Buren
- Catherine KimCKCatherine Kim
- Wanpen VongpatanasinWVWanpen Vongpatanasin
- Thomas J. PovsicTPThomas J. Povsic
- Robert TotoRTRobert Toto
- 1 August 2012
- journal article
- research article
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 7 (8) , 1300-1309
Abstract
Summary: Background and objectives: Intradialytic hypertension may be caused by an impaired endothelial cell response to hemodialysis. Carvedilol has been shown to improve endothelial cell function in vivo and to block endothelin-1 release in vitro. This study hypothesized that carvedilol would improve endothelial cell function and reduce the occurrence of intradialytic hypertension. Design, setting, participants, & measurements: A prospective 12-week pilot study of carvedilol titrated to 50 mg twice daily was performed among 25 hemodialysis participants with intradialytic hypertension. Each patient served as his or her own control. Paired tests were used to analyze changes in BP and endothelial cell function—assessed by flow-mediated vasodilation, endothelial progenitor cells (aldehyde dehydrogenase bright activity and CD34+CD133+), asymmetric dimethylarginine, and endothelin-1—from baseline to study end. Results: Flow-mediated vasodilation was significantly improved with carvedilol (from 1.03% to 1.40%, P=0.02). There was no significant change in endothelial progenitor cells, endothelin-1, or asymmetric dimethylarginine. Although prehemodialysis systolic BP was unchanged (144–146 mmHg, P=0.5), posthemodialysis systolic BP, 44-hour ambulatory systolic BP, and the frequency of intradialytic hypertension decreased with carvedilol (159–142 mmHg, PP=0.05; and 77% [4.6 of 6] to 28% [1.7 of 6], P<0.001, respectively). Conclusions: Among hemodialysis participants with intradialytic hypertension, targeting endothelial cell dysfunction with carvedilol was associated with modest improvements in endothelial function, improved intradialytic and interdialytic BP, and reduced frequency of intradialytic hypertension. Randomized controlled trials are required to confirm these findings.Keywords
This publication has 26 references indexed in Scilit:
- Aortic pulse wave velocity in renal transplant patientsKidney International, 2004
- Forearm reactive hyperemia and mortality in end-stage renal diseaseKidney International, 2004
- Predictive value of noninvasivelydetermined endothelial dysfunction for long-term cardiovascular events inpatients with peripheral vascular diseaseJACC, 2003
- Circulating Endothelial Progenitor Cells, Vascular Function, and Cardiovascular RiskNew England Journal of Medicine, 2003
- Hemodynamic changes during hemodialysis: Role of nitric oxide and endothelinKidney International, 2002
- Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial arteryJACC, 2002
- Supervised atenolol therapy in the management of hemodialysis hypertensionKidney International, 1999
- Carvedilol and its Metabolites Suppress Endothelin-1 Production in Human Endothelial Cell CultureBlood Pressure, 1997
- ‘Paradoxical’ rise in blood pressure during ultrafiltration in dialysis patientsNephrology Dialysis Transplantation, 1995
- Prevention of Intra- and Postdialytic Hypertensive Crises by Captopril1984